Use of omalizumab in the treatment of chronic urticaria

A.S. Cordeiro Moreira, M.I. Rosmaninho Lopes de Soares e Silva, M.A. Pereira Guilherme, J.A. da Silva Ferreira, J.P. Fonseca Moreira da Silva

Background. Omalizumab is indicated to treat chronic spontaneous urticaria (CSU) refractory to antihistamines. We aim to describe the experience of our department in the treatment of CSU with omalizumab. Materials and Methods. Retrospective review of the clinical records of patients. Results. Six patients (5 females, median age 33 years) treated with omalizumab for a median of 17.5 months were evaluated. All patients had improvement of symptoms after the first dose. In one case, the treatment was suspended after 7 months, but in 9 weeks there
was recurrence of symptoms. The main side effect was headache in the drug administration's day. Currently, all patients maintain therapy with omalizumab and are clinically stable. Conclusion. Omalizumab proved to be an effective and safe drug for the treatment of patients with refractory CSU.
FULL TEXT